Meningitis - Pipeline Review, H1 2016

Description: Meningitis - Pipeline Review, H1 2016

Summary

'Meningitis - Pipeline Review, H1 2016', provides an overview of the Meningitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meningitis
- The report reviews pipeline therapeutics for Meningitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Meningitis therapeutics and enlists all their major and minor projects
- The report assesses Meningitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Meningitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Meningitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Meningitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Meningitis Overview
Therapeutics Development
Pipeline Products for Meningitis - Overview
Pipeline Products for Meningitis - Comparative Analysis
Meningitis - Therapeutics under Development by Companies
Meningitis - Therapeutics under Investigation by Universities/Institutes
Meningitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Meningitis - Products under Development by Companies
Meningitis - Products under Investigation by Universities/Institutes
Meningitis - Companies Involved in Therapeutics Development
Adenium Biotech ApS
Amplyx Pharmaceuticals, Inc.
Chiesi Farmaceutici SpA
ContraFect Corporation
Genticel S.A.
LG Life Science LTD.
Matinas BioPharma Holdings, Inc.
Sanofi Pasteur SA
Viamet Pharmaceuticals, Inc.
Meningitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eupenta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meropenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus pneumonia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tuberculous meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
viral vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015

Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta

Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129

Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants

Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease

Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease

Feb 22, 2010: Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease

Jun 30, 2009: Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo

May 06, 2008: Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial

Jan 09, 2008: New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants

Nov 15, 2007: New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Meningitis - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3775432/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Product</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise wide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: _______________________________
Email Address: * ___________________________________________
Job Title: ___________________________________________
Organisation: ___________________________________________
Address: ___________________________________________
City: ___________________________________________
Postal / Zip Code: ___________________________________________
Country: ___________________________________________
Phone Number: ___________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.
- Pay by check: Please post the check, accompanied by this form, to:
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.
- Pay by wire transfer: Please transfer funds to:
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World